Lunit INSIGHT MMG in clinical use

Lunit to Provide AI Platform to Australian BreastScreen NSW Machine Reading Project | BioSpace

  • Lunit’s INSIGHT MMG solution has been selected for mammography screening as part of BreastScreen NSW’s AI Assessment and Clinical Integration Project in Australia
  • Successful completion of the project will be followed by a 5-year operating contract with BSNSW to help radiologists examine 350,000 women per year

SEOUL, South Korea, Nov. 16, 2022 /PRNewswire/ — lunit (KRX: 328130.KQ), a leading medical AI provider serving more than 1,000 sites worldwide, today announced that it has signed a contract to provide its AI solution for the State BreastScreen NSW (BSNSW), managed by the Cancer Institute NSW (New South Wales Cancer Agency). Lunit’s selection as the program’s provider marks the first instance in the world in which an AI-based solution is deployed by a national cancer screening organization.

In 2021, Cancer Institute NSW solicited proposals and test results from potential vendors for the supply, execution and/or delivery of a state-of-the-art BreastScreen machine reading solution, based on the latest generation of technology deep machine learning AI for detecting cancers during screening. mammograms. Lunit INSIGHT MMG, an AI solution for mammography analysis, was named the preferred solution for this project.

Lunit INSIGHT MMG in clinical use

BSNSW is part of the national BreastScreen Australia programme, which is jointly funded by the Commonwealth and state and territory governments with the aim of improving survival rates for women with breast cancer. The service aims to detect breast cancer early by offering free mammograms to women aged 40 and over.

Phase 1 of the BSNSW Machine Reading Project will validate the Lunit INSIGHT MMG solution to confirm potential clinical benefits prior to operational deployment. Lunit’s AI solution will analyze and validate approximately 650,000 mammograms against historical reports provided by BSNSW radiologists.

Phase 2 will perform prospective validation of Lunit INSIGHT MMG in the planned workflow by evaluating approximately 240,000 exams over an 8-month period. The results will be analyzed alongside the reports from the radiologists to ensure an optimal integrated and secure workflow.

In phase 3, operational deployment will see the Lunit INSIGHT MMG solution integrated into the BSNSW PACS environment, assisting radiologists with all screening exams for approximately 350,000 women per year. During this final phase, additional evaluations will be conducted to validate Lunit INSIGHT DBT, an AI solution for digital breast tomosynthesis, for clinical use.

Upon successful completion of all three phases, Lunit will be awarded a 5-year operational contract with BSNSW, which should further secure supply and operations across Australia.

“This is the first time Lunit has had the opportunity to provide our AI solution for a national breast cancer screening program,” said Lunit CEO Brandon Suh. “We plan to proactively prepare for the growing demand for national screening programs around the world, in addition to actively pursuing new business opportunities.”

About Lunit

With AI, Lunit aims to “beat cancer”, one of the main causes of death in the world. Lunit is an AI software company dedicated to developing AI solutions for precision diagnostics and therapeutics, to find the right diagnosis at the right cost and the right treatment for the right patients. Lunit, a portmanteau of the “learning unit”, is a deep learning-based medical AI company dedicated to the development of advanced medical image analytics and imaging biomarkers based on data through state-of-the-art technology.

Founded in 2013, Lunit is recognized worldwide for its advanced technology and application in medical images. Its technology has been recognized in international AI competitions surpassing the biggest companies like Google, IBM and Microsoft. As a medical AI company that values ​​the creation of clinical evidence, the company’s results are featured in leading peer-reviewed journals such as the Journal of Clinical Oncology and JAMA Network Open, and at global conferences such as ASCO and AACR. After receiving FDA clearance and CE Mark, Lunit INSIGHT CXR and MMG are clinically used in approximately 1,000 hospitals and medical institutions in more than 40 countries. Lunit is headquartered in Seoul, South Korea, with offices and representatives in the United States, the Netherlands, and China.


Quote View original content to download multimedia:


Company Codes: Korea: 328130

#Lunit #Provide #Platform #Australian #BreastScreen #NSW #Machine #Reading #Project #BioSpace

Leave a Comment

Your email address will not be published. Required fields are marked *